On ECHEMI
Home > Drugs > Venturpharm Pharmaceutical(Hainan)Limited.
Venturpharm Pharmaceutical(Hainan)Limited.
  • Founded in:

    2004-03-09
  • Country:

    China China
  • Address:

    No. 279 Nanhai Avenue, Haikou City
  • Tax NO.:

    914601007543894388
  • Registered Funds:

    194.8706 million yuan
  • Email:

Related Drugs
Trimetazidine hydrochloride
Name Description Content CAS NO. Registered Holders
Trimetazidine dihydrochloride

13171-25-0 31
Bisoprolol Fumarate
Name Description Content CAS NO. Registered Holders
Bisoprolol fumarate

Pharmacological action not specified

More

Pharmacological action not specified

104344-23-2 47
Loratadine Sustained-Release Tablets
This product is a compound preparation, its components are 10 mg of loratadine and 248 mg of pseudoephedrine sulfate.
Name Description Content CAS NO. Registered Holders
Loratadine

It is a long-acting tricyclic antihistamine that can relieve nasal or non-nasal symptoms of seasonal allergic rhinitis by selectively antagonizing peripheral H1 receptors.

More

It is a long-acting tricyclic antihistamine that can relieve nasal or non-nasal symptoms of seasonal allergic rhinitis by selectively antagonizing peripheral H1 receptors.

10mg 79794-75-5 61
Pseudoephedrine sulfate

It is an adrenaline-mimetic drug that can constrict the blood vessels of the nasal mucosa and relieve symptoms of nasal congestion and runny nose.

More

It is an adrenaline-mimetic drug that can constrict the blood vessels of the nasal mucosa and relieve symptoms of nasal congestion and runny nose.

248mg 0
Fexofenadine Hydrochloride
Name Description Content CAS NO. Registered Holders
Fexofenadine hydrochloride

Extract from the above information

More

Extract from the above information

153439-40-8 49
Alendronate Sodium Tablets
Alendronate
Name Description Content CAS NO. Registered Holders
Alendronate sodium

This product is a bone metabolism regulator, an aminobisphosphonate, which has a strong affinity with hydroxyapatite in the bone. It can enter the hydroxyapatite crystals in the bone matrix. When osteoclasts dissolve the crystals, the drug is released, which can inhibit the activity of osteoclasts and indirectly inhibit bone resorption through osteoblasts. It is characterized by strong anti-bone resorption activity and no bone mineralization inhibition.

More

This product is a bone metabolism regulator, an aminobisphosphonate, which has a strong affinity with hydroxyapatite in the bone. It can enter the hydroxyapatite crystals in the bone matrix. When osteoclasts dissolve the crystals, the drug is released, which can inhibit the activity of osteoclasts and indirectly inhibit bone resorption through osteoblasts. It is characterized by strong anti-bone resorption activity and no bone mineralization inhibition.

121268-17-5 38
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.